| 07/22/2026 16:00 |
Notice Regarding the Completion of Payment for the Disposition of Treasury Stock as Restricted Stock Compensation |
| 07/21/2026 13:30 |
JCR Pharmaceuticals Receives Marketing Authorization in the United Arab Emirates for IZCARGO, Therapy for Hunter Syndrome |
| 07/15/2026 08:30 |
JCR Pharmaceuticals Announces Development Plan in Japan for Givinostat for Duchenne Muscular Dystrophy |
| 06/23/2026 16:00 |
Partial Correction: Consolidated Financial Results for the Full Year ended March 31, 2026 (FY2025)(Japanese standard) |
| 06/23/2026 16:00 |
Partial Correction: Consolidated Financial Results for the Full Year ended March 31, 2025 (FY2024)(Japanese standard) |
| 06/23/2026 16:00 |
Matters Concerning Controlling Shareholders (Affiliated Companies) |
| 06/23/2026 16:00 |
Notice Regarding the Disposition of Treasury Stock as Restricted Stock Compensation |
| 06/01/2026 08:00 |
Other Matters Subject to Measures for Electronic Provision When Convening the 51st Ordinary General Meeting of Shareholders |
| 06/01/2026 08:00 |
Notice of Convocation of The 51st Ordinary General Meeting of Shareholders |
| 05/28/2026 16:00 |
JCR Pharmaceuticals to Present at the 18th International Symposium on MPS and Related Lysosomal Diseases 2026 |
| 05/18/2026 16:00 |
JCR Pharmaceuticals Presents Preclinical Gene Therapy Data that Demonstrate Promising Central Nervous System Uptake at the ASGCT 29th Annual Meeting |
| 05/13/2026 17:05 |
Notice Concerning Partial Corrections to the Annual Securities Report for Past Fiscal Years and the Consolidated Financial Results for the Nine Months |
| 05/13/2026 15:30 |
Consolidated Financial Results for the Year ended March 31, 2026 (FY2025)(Japanese standard) |
| 05/13/2026 15:30 |
FY2025 Results Briefing Session Material |
| 05/11/2026 16:00 |
JCR Pharmaceuticals to Present at the American Society of Gene and Cell Therapy (ASGCT) 29th Annual Meeting |
| 05/11/2026 15:30 |
Revision of Consolidated Financial Forecasts for Fiscal Year Ended March 31, 2026 |
| 04/24/2026 15:30 |
Notice of Personnel Change |
| 04/24/2026 15:30 |
Notice of Election of Candidate for New Outside Director |
| 04/13/2026 16:00 |
JCR Pharmaceuticals Initiates Phase III Dose Comparison Study of GROWJECT S.C. Injection 12mg in Japan |
| 04/01/2026 11:45 |
JCR Pharmaceuticals Launches Redesigned Corporate Website |
| 02/26/2026 16:00 |
Announcement of Executive Appointments and Organizational Changes |
| 02/26/2026 16:00 |
JCR Establishes Advanced Biopharmaceutical Research Institute |
| 02/20/2026 16:00 |
JCR Pharmaceuticals Supports Rare Disease Day 2026 |
| 02/16/2026 16:00 |
JCR Organizes and Conducts API Plant Tour for Individual Shareholders |
| 01/28/2026 17:00 |
FY2025 Third Quarter Results Briefing Session Material |
| 01/28/2026 17:00 |
Recognition of Subsidy Income as Extraordinary Income |
| 01/28/2026 17:00 |
Consolidated Financial Results for the Nine Months ended December 31, 2025(FY2025) (Japanese standard) |
| 01/28/2026 17:00 |
Revision of Consolidated Financial Forecasts for Fiscal Year Ended March 31, 2026 |
| 01/27/2026 15:00 |
JCR Pharmaceuticals to Present at the 22nd Annual WORLDSymposium 2026 |
| 01/23/2026 14:30 |
Briefing Session Material on the Agreement with Italfarmaco |
| 01/08/2026 13:00 |
JCR Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference |
| 12/24/2025 08:30 |
Italfarmaco and JCR Pharmaceuticals Announce Commercialisation Agreement for Givinostat in Japan and Strategic Collaboration in Rare Disease |
| 12/18/2025 16:00 |
Notice of Personnel Change |
| 11/26/2025 15:00 |
JCR Organizes and Conducts API Plant Tour for Local Residents |
| 10/30/2025 14:00 |
FY2025 Second Quarter Results Briefing Session Material |
| 10/30/2025 14:00 |
Consolidated Financial Results for the Six Months ended September 30, 2025 (FY2025) (Japanese standard) |
| 10/17/2025 16:00 |
Shin Ashida of JCR Pharmaceuticals Named Kansai Regional Representative in EY Entrepreneur of The Year(TM) 2025 Japan |
| 10/07/2025 16:00 |
JCR Pharmaceuticals Enhances Delivery of AAV Gene Therapy to Central Nervous System and Muscle with Novel Capsid Engineering Platform Technology |
| 10/01/2025 16:00 |
JCR Pharmaceuticals Announces Licensing Agreement with Menagen to Commercialize Agalsidase Beta BS I.V. Infusion [JCR] Across Nine MENAT Markets |
| 09/30/2025 18:30 |
Corporate Gavanance Report |
| 09/30/2025 16:00 |
JCR Pharmaceuticals to Present at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress |
| 09/29/2025 16:50 |
Notice of Orphan Drug Designation for JR-446 for Mucopolysaccharidosis Type IIIB by Ministry of Health, Labour and Welfare of Japan |
| 09/25/2025 16:00 |
Notice of Personnel Change |
| 09/19/2025 16:00 |
JCR Pharmaceuticals and Alexion Achieve Milestone in Collaborative Neurodegenerative Disease Program |
| 09/18/2025 16:00 |
Notice of Personnel Change |
| 09/12/2025 11:00 |
JCR Pharmaceuticals Celebrates its 50th Anniversary of Advancing Science and Changing Lives |
| 09/08/2025 16:00 |
JCR Pharmaceuticals Sponsors and Participates in Relay For Life of Ashiya |
| 09/08/2025 16:00 |
JCR Pharmaceuticals Presents Long-Term Clinical Data on Pabinafusp Alfa for the Treatment of Mucopolysaccharidosis Type II (MPS II) at ICIEM 2025 |
| 09/04/2025 16:00 |
Notice of Organizational and Personnel Changes |
| 09/01/2025 16:00 |
Notice of Personnel Change |
| 09/01/2025 14:00 |
PHC and JCR GROWJECTOR L Automated Injection Device Wins 2025 Kids Design Award |
| 08/29/2025 15:30 |
MEDIPAL HOLDINGS and JCR Pharmaceuticals Sign Global Licensing and Japan Co-Development Agreement for JR-479, a Novel Therapy for GM2 Gangliosidosis |
| 08/28/2025 11:00 |
JCR Pharmaceuticals to Present at the 15th International Congress of Inborn Errors of Metabolism (ICIEM) 2025 |
| 08/01/2025 17:00 |
Corporate Governance Report |
| 07/30/2025 16:00 |
FY2025 First Quarter Results Conference Call Material |
| 07/30/2025 16:00 |
Financial Summary Consolidated Financial Results for the Three Months ended June 30, 2025 (FY2025) (Japanese standard) |
| 07/28/2025 16:00 |
JCR Receives National Honor for Supporting Children with Complex Medical Needs |
